Stage-associated differences in the serum N- and O-glycan profiles of patients with non-small cell lung cancer

作     者：Liang, Yiqian Han, Peng Wang, Ting Ren, Hui Gao, Lei Shi, Puyu Zhang, Shuo Yang, Aimin Li, Zheng Chen, Mingwei 

作者机构：Xi An Jiao Tong Univ Affiliated Hosp 1 Dept Resp & Crit Care Med Xian 710061 Shaanxi Peoples R China Xi An Jiao Tong Univ Affiliated Hosp 1 Dept Nucl Med Xian 710061 Shaanxi Peoples R China Northwest Univ Coll Life Sci Lab Funct Glyc Xian 710069 Shaanxi Peoples R China Xi An Jiao Tong Univ Affiliated Hosp 1 Dept Otolaryngol Head & Neck Surg Xian 710061 Shaanxi Peoples R China Xian 4 Hosp Dept Resp Med Xian 710004 Shaanxi Peoples R China Xi An Jiao Tong Univ Affiliated Hosp 2 Dept Endocrinol Xian 710004 Shaanxi Peoples R China Xi An Jiao Tong Univ Affiliated Hosp 1 Dept Radiol Xian 710061 Shaanxi Peoples R China 

出 版 物：《CLINICAL PROTEOMICS》 (临床蛋白质组学)

年 卷 期：2019年第16卷第1期

页      面：20-20页

核心收录：

学科分类：0710[理学-生物学] 071010[理学-生物化学与分子生物学] 07[理学] 

基　　金：Collaboration Project of International Science and Technology of Shaanxi Province [2018KW-039] Key Research and Development Program of Shaanxi Province [2018SF-219] Fundamental Research Funds for the Central Universities in Xi'an Jiaotong University [xjj2018094] 

主　　题：Non-small cell lung cancer Protein glycosylation Serum biomarkers Lectin microarray Glycomics 

摘      要：BackgroundLung cancer is the leading cause of cancer death in China and around the world. Early detection is key to improving the survival rate of non-small cell lung cancer (NSCLC). Alteration in glycosylation has been observed in cancers, and glycans can be a source for the development of new biomarkers for *** this glycan biomarker discovery study, we measured serum N- and O-glycan profiles in NSCLC patients with different stages and healthy controls by performing lectin microarray analysis. The alterations of serum glycopatterns were compared between NSCLC patients and controls, and the stage-related changes in serum glycosylation were *** were 18 lectins (e.g., AAL, Jacalin, GSL-I and DBA) to give significantly alterations of serum glycopatterns in lung adenocarcinoma compared with control group. Meanwhile, 16 lectins (e.g., Jacalin, HHL, and PHA-E+L) exhibited significantly alterations of serum glycopatterns in squamous cell carcinoma (SCC) compared with control group. Importantly, most of the lectins showing altered signals exhibited significantly increased or decreased NFIs in patients with early stage adenocarcinoma and *** serum glycan profiles were significantly different between NSCLC and healthy control, and most of the glycosylation changes had occurred at early stage. Further evaluation is needed to examine the diagnostic value of the glycan markers identified in this study.